AUS
NZ
UK
CA
USA
IND
Highlights
- EBOS raises $200 million through equity placement
- Funds to support recent acquisitions and growth
- Additional $50 million targeted via retail offer
Healthcare and animal care products distributor EBOS Group (ASX:EBO) has successfully raised NZ$200 million through an institutional equity placement, with the funds earmarked to support recent acquisitions and further strategic expansion.
The placement was priced at NZ$36.65 per share, representing a 5% discount compared to its previous closing price of NZ$38.56 on the New Zealand Exchange (NZX). Despite the discounted offer, the company reported strong participation from both existing and new investors across New Zealand, Australia, and international markets.
This capital raise forms part of a broader funding strategy that includes an upcoming retail offer. EBOS is planning to raise up to NZ$50 million more from eligible shareholders, providing a further opportunity for investor participation.
The proceeds are set to underpin EBOS Group’s recent purchase of SVS Veterinary Supplies, a wholesale business servicing the veterinary sector in Australia. Additionally, the funds will aid in the complete acquisition of Transmedic, a medical device distributor operating across Southeast Asia.
These acquisitions reflect EBOS Group’s ongoing strategy to diversify its portfolio and strengthen its presence in both human and animal health sectors. The company highlighted that any surplus capital from the raise will contribute to maintaining balance sheet flexibility, supporting potential future investments or expansion initiatives.
EBOS has steadily built a reputation for growth through targeted acquisitions and cross-border partnerships. With its dual listing on both the ASX and NZX, the company continues to attract investor interest from a wide geographical base.
The latest funding effort indicates continued confidence in the company’s long-term growth path, especially as it deepens its footprint in emerging healthcare and veterinary markets. The focus on infrastructure expansion and broader product distribution aligns with EBOS Group’s broader vision of becoming a leading player across the Asia-Pacific health sector.
As the company progresses with integrating its new acquisitions, market observers will be closely watching how these moves translate into enhanced operational scale and revenue growth.
